Cargando…

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma

Belantamab mafodotin, a monomethyl auristatin F (MMAF)–containing monoclonal antibody‐drug conjugate (ADC), demonstrated deep and durable responses in the DRiving Excellence in Approaches to Multiple Myeloma (DREAMM)‐1 and pivotal DREAMM‐2 studies in patients with relapsed/refractory multiple myelom...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Jon, van Noort, Martijn, Rathi, Chetan, Post, Teun M., Struemper, Herbert, Jewell, Roxanne C., Ferron‐Brady, Geraldine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583243/
https://www.ncbi.nlm.nih.gov/pubmed/37465991
http://dx.doi.org/10.1002/psp4.13016
_version_ 1785122509814759424
author Collins, Jon
van Noort, Martijn
Rathi, Chetan
Post, Teun M.
Struemper, Herbert
Jewell, Roxanne C.
Ferron‐Brady, Geraldine
author_facet Collins, Jon
van Noort, Martijn
Rathi, Chetan
Post, Teun M.
Struemper, Herbert
Jewell, Roxanne C.
Ferron‐Brady, Geraldine
author_sort Collins, Jon
collection PubMed
description Belantamab mafodotin, a monomethyl auristatin F (MMAF)–containing monoclonal antibody‐drug conjugate (ADC), demonstrated deep and durable responses in the DRiving Excellence in Approaches to Multiple Myeloma (DREAMM)‐1 and pivotal DREAMM‐2 studies in patients with relapsed/refractory multiple myeloma. As with other MMAF‐containing ADCs, ocular adverse events were observed. To predict the effects of belantamab mafodotin dosing regimens and dose‐modification strategies on efficacy and ocular safety end points, DREAMM‐1 and DREAMM‐2 data across a range of doses were used to develop an integrated simulation framework incorporating two separate longitudinal models and the published population pharmacokinetic model. A concentration‐driven tumor growth inhibition model described the time course of serum M‐protein concentration, a measure of treatment response, whereas a discrete time Markov model described the time course of ocular events graded with the GSK Keratopathy and Visual Acuity scale. Significant covariates included baseline β(2)‐microglobulin on growth rate, baseline M‐protein on kill rate, extramedullary disease on the effect compartment rate constant, and baseline soluble B cell maturation antigen on maximal effect. Efficacy and safety end points were simulated for various doses with dosing intervals of 1, 3, 6, and 9 weeks and various event‐driven dose‐modification strategies. Simulations predicted that lower doses and longer dosing intervals were associated with lower probability and lower overall time with Grade 3+ and Grade 2+ ocular events compared with the reference regimen (2.5 mg/kg every 3 weeks), with a less‐than‐proportional reduction in efficacy. The predicted improved benefit–risk profiles of certain dosing schedules and dose modifications from this integrated framework has informed trial designs for belantamab mafodotin, supporting dose‐optimization strategies.
format Online
Article
Text
id pubmed-10583243
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105832432023-10-19 Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma Collins, Jon van Noort, Martijn Rathi, Chetan Post, Teun M. Struemper, Herbert Jewell, Roxanne C. Ferron‐Brady, Geraldine CPT Pharmacometrics Syst Pharmacol Research Belantamab mafodotin, a monomethyl auristatin F (MMAF)–containing monoclonal antibody‐drug conjugate (ADC), demonstrated deep and durable responses in the DRiving Excellence in Approaches to Multiple Myeloma (DREAMM)‐1 and pivotal DREAMM‐2 studies in patients with relapsed/refractory multiple myeloma. As with other MMAF‐containing ADCs, ocular adverse events were observed. To predict the effects of belantamab mafodotin dosing regimens and dose‐modification strategies on efficacy and ocular safety end points, DREAMM‐1 and DREAMM‐2 data across a range of doses were used to develop an integrated simulation framework incorporating two separate longitudinal models and the published population pharmacokinetic model. A concentration‐driven tumor growth inhibition model described the time course of serum M‐protein concentration, a measure of treatment response, whereas a discrete time Markov model described the time course of ocular events graded with the GSK Keratopathy and Visual Acuity scale. Significant covariates included baseline β(2)‐microglobulin on growth rate, baseline M‐protein on kill rate, extramedullary disease on the effect compartment rate constant, and baseline soluble B cell maturation antigen on maximal effect. Efficacy and safety end points were simulated for various doses with dosing intervals of 1, 3, 6, and 9 weeks and various event‐driven dose‐modification strategies. Simulations predicted that lower doses and longer dosing intervals were associated with lower probability and lower overall time with Grade 3+ and Grade 2+ ocular events compared with the reference regimen (2.5 mg/kg every 3 weeks), with a less‐than‐proportional reduction in efficacy. The predicted improved benefit–risk profiles of certain dosing schedules and dose modifications from this integrated framework has informed trial designs for belantamab mafodotin, supporting dose‐optimization strategies. John Wiley and Sons Inc. 2023-08-02 /pmc/articles/PMC10583243/ /pubmed/37465991 http://dx.doi.org/10.1002/psp4.13016 Text en © 2023 GSK. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Collins, Jon
van Noort, Martijn
Rathi, Chetan
Post, Teun M.
Struemper, Herbert
Jewell, Roxanne C.
Ferron‐Brady, Geraldine
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
title Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
title_full Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
title_fullStr Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
title_full_unstemmed Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
title_short Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
title_sort longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583243/
https://www.ncbi.nlm.nih.gov/pubmed/37465991
http://dx.doi.org/10.1002/psp4.13016
work_keys_str_mv AT collinsjon longitudinalefficacyandsafetymodelingandsimulationframeworktoaiddoseselectionofbelantamabmafodotinforpatientswithmultiplemyeloma
AT vannoortmartijn longitudinalefficacyandsafetymodelingandsimulationframeworktoaiddoseselectionofbelantamabmafodotinforpatientswithmultiplemyeloma
AT rathichetan longitudinalefficacyandsafetymodelingandsimulationframeworktoaiddoseselectionofbelantamabmafodotinforpatientswithmultiplemyeloma
AT postteunm longitudinalefficacyandsafetymodelingandsimulationframeworktoaiddoseselectionofbelantamabmafodotinforpatientswithmultiplemyeloma
AT struemperherbert longitudinalefficacyandsafetymodelingandsimulationframeworktoaiddoseselectionofbelantamabmafodotinforpatientswithmultiplemyeloma
AT jewellroxannec longitudinalefficacyandsafetymodelingandsimulationframeworktoaiddoseselectionofbelantamabmafodotinforpatientswithmultiplemyeloma
AT ferronbradygeraldine longitudinalefficacyandsafetymodelingandsimulationframeworktoaiddoseselectionofbelantamabmafodotinforpatientswithmultiplemyeloma